Investors
Where Innovation Meets Impact.
AI-Powered Platforms Transforming Digital Health and Driving Shareholder Value
Why Invest in AIML?
CSE: AIML
OTCQB: AIMLF
FWB: 42FB
We are pioneering the future of health intelligence by developing and commercializing advanced AI-driven technologies that unlock powerful biometric insights
Backed by a growing portfolio of proprietary technologies and a world-class leadership team, AIML is committed to delivering long-term value to shareholders while improving health outcomes across global markets.
Press Releases
Read more in Archive
December 16, 2025
Join AIML’s Live Shareholder Update with Chairman & CEO Paul Duffy
Read More
December 9, 2025
AIML subsidiary NeuralCloud Solutions Signs Commercial Term Sheet with Culminate H Labs to Deploy MaxYield™ and Insight360™ into INTRINSICA's DNA-Guided Biofeedback Wellness Ecosystem
Read More
December 2, 2025
AIML subsidiary NeuralCloud Enters Pilot with Cornerstone Physiotherapy to Deploy MaxYield™ and Insight360™ for Elite Athlete Cardiac Performance Testing
Read More
November 26, 2025
AIML subsidiary NeuralCloud Signs Commercial Term Sheet with Equimetrics to Deploy MaxYield™ and CardioYield™ across Equine Cardiac Monitoring Platforms
Read More
November 24, 2025
AIML subsidiary Neural Cloud begins pilot at SickKids to Advance AI-Enabled Pediatric Cardiac Care
Read More
November 11, 2025
AI/ML Innovations Inc. Announces Grant of U.S. Patent Protecting Core ECG Signal-Processing Architecture
Read More
Corporate Governance
Board of Directors
Financials
Read more on CSE
Read more
Charters & Policies
Company Structure
253.9
Million
Shares Outstanding
16
Million
Options
190.7
Million
Warrants Outstanding
460.6
Million
Fully Diluted